![]() |
Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
Meng-Che Wu, Hui-Chin Chang, Yi-Sheng Jhang, Shuo-Yan Gau
Clin Mol Hepatol. 2025;31(1):e13-e14. Published online 2024 Sep 2 DOI: https://doi.org/10.3350/cmh.2024.0682
|
Citations to this article as recorded by
Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clinical and Molecular Hepatology.2025; 31(1): e98. CrossRef
|